Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.01.18	Regeneron Announces Approval Of DUPIXENT In Japan - Quick Facts (RTTNews)
22.01.18	Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis (PR Newswire)
08.01.18	Infor Releases New Digital Innovation Enabler for Healthcare Industry (PR Newswire)
08.01.18	Sanofi, Regeneron To Expand Investment For Cemiplimab & Dupilumab Development (RTTNews)
08.01.18	Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs (PR Newswire)
08.01.18	Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank (PR Newswire)
21.12.17	Vertek Corporation Partners With VeloCloud to Provide Remote Management & Monitoring (RMM) and Helpdesk Services (PR Newswire)
18.12.17	Regeneron, ISA Pharma Announce Strategic Immuno-Oncology Collaboration (RTTNews)
18.12.17	Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration (PR Newswire)
13.12.17	Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day (PR Newswire)
13.12.17	Regeneron, Sanofi Report Results For PD-1 Antibody Cemiplimab In Advanced CSCC (RTTNews)
13.12.17	Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
11.12.17	Regeneron Says FDA Accepts SBLA Filing For 12-week Dosing Of Eylea Injection (RTTNews)
11.12.17	Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD (PR Newswire)
10.12.17	Repatha & Praluent: A Tale Of Two Rivals... (RTTNews)
30.11.17	TXMD Giving A 2nd Try, PLX On Watch, NAOV's Shield Against Suicide Disease (RTTNews)
29.11.17	Regeneron Pharma, Decibel Announce Collaboration - Quick Facts (RTTNews)
29.11.17	Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus (PR Newswire)
28.11.17	BIIB & ALKS Team Up For MS Drug, REGN's Eylea Combo Fails Again, AEZS Rises (RTTNews)
27.11.17	Regeneron Updates On EYLEA Injection And Nesvacumab Combination Program (RTTNews)
27.11.17	Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program (PR Newswire)
24.11.17	RD Training Systems Is Coming to Salt Lake City, Utah in December 2017 (PR Newswire)
15.11.17	Regeneron Announces Upcoming Investor Conference Presentation (PR Newswire)
08.11.17	Regeneron Pharmaceuticals Earnings Rise 29% In Q3 (RTTNews)
08.11.17	Regeneron Reports Third Quarter 2017 Financial and Operating Results (PR Newswire)
07.11.17	Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017 (PR Newswire)
01.11.17	Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting (PR Newswire)
31.10.17	Regeneron And Sanofi Say Phase 3 Study On Dupilumab Meets Primary Endpoint (RTTNews)
31.10.17	Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma (PR Newswire)
27.10.17	Philip Sweet, M.S.N., R.N., PMHCNS-BC, NP is recognized by Continental Who's Who (PR Newswire)
27.10.17	Regeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations (PR Newswire)
24.10.17	IT and Management Consulting Firm Enlightened Selects 5WPR as AOR to Increase Brand Awareness as it Expands into Commercial (PR Newswire)
23.10.17	DBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRS (RTTNews)
19.10.17	Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time (PR Newswire)
16.10.17	Regeneron Pharma, Sanofi Announce Positive Phase 2 Study Results For Dupilumab (RTTNews)
16.10.17	Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis (PR Newswire)
11.10.17	Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017 (PR Newswire)
11.10.17	Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis (PR Newswire)
05.10.17	Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab) (PR Newswire)
03.10.17	VOXX International Corporation Sets Date For Its Fiscal 2018 Second Quarter Results And Conference Call (PR Newswire)
02.10.17	Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens (PR Newswire)
28.09.17	Sanofi, Regeneron: Dupixent Gets EU Approval To Treat Atopic Dermatitis (RTTNews)
28.09.17	Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union (PR Newswire)
21.09.17	ELOQUII Debuts Exclusive Capsule Collection With Digital Influencer & Style Expert, Katie Sturino (PR Newswire)
16.09.17	Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis (PR Newswire)
14.09.17	Stocks Under Scanner in the Biotech Space -- Puma Biotech, Regeneron Pharma, Sarepta Therapeutics, and Seattle Genetics (PR Newswire)
13.09.17	Smart Medical Device Could Save Millions of Lives (PR Newswire)
12.09.17	Companies to Watch as Biotech Makes a Comeback in 2017 (PR Newswire)
11.09.17	Sanofi, Regeneron: Dupilumab Meets Main Objectives In Late-Stage Asthma Trial (RTTNews)
11.09.17	Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	534.20	0.60 %	K V
Sonova Hldg	305.30	0.23 %	K V
Alcon	77.70	0.10 %	K V
Roche Hldg G	251.60	0.08 %	K V
Novartis	91.97	0.04 %	K V
UBS Group	27.53	-0.83 %	K V
CieFinRichemont	121.25	-0.90 %	K V
ABB	49.05	-0.99 %	K V
Sika	225.10	-1.53 %	K V
Logitech Intl	70.42	-2.17 %	K V

mehr

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

31.10.24

NASDAQ-Handel NASDAQ 100 schlussendlich in Rot

31.10.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone

31.10.24

NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell

31.10.24

Zurückhaltung in New York: So performt der NASDAQ 100 aktuell

31.10.24

Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus